ATE121091T1 - Phospholipase a2-inhibitor, mikroorganismen, die diesen inhibitor erzeugen und mehrere verfahren zu seiner herstellung. - Google Patents

Phospholipase a2-inhibitor, mikroorganismen, die diesen inhibitor erzeugen und mehrere verfahren zu seiner herstellung.

Info

Publication number
ATE121091T1
ATE121091T1 AT90306872T AT90306872T ATE121091T1 AT E121091 T1 ATE121091 T1 AT E121091T1 AT 90306872 T AT90306872 T AT 90306872T AT 90306872 T AT90306872 T AT 90306872T AT E121091 T1 ATE121091 T1 AT E121091T1
Authority
AT
Austria
Prior art keywords
inhibitor
producing
phospholipase
coor
compound
Prior art date
Application number
AT90306872T
Other languages
English (en)
Inventor
Tadashi Yoshida
Hitoshi Arita
Koichi Matsumoto
Hiroshi Itazaki
Yoshimi Kawamura
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE121091T1 publication Critical patent/ATE121091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungi isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
AT90306872T 1989-06-30 1990-06-22 Phospholipase a2-inhibitor, mikroorganismen, die diesen inhibitor erzeugen und mehrere verfahren zu seiner herstellung. ATE121091T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17039689 1989-06-30

Publications (1)

Publication Number Publication Date
ATE121091T1 true ATE121091T1 (de) 1995-04-15

Family

ID=15904154

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90306872T ATE121091T1 (de) 1989-06-30 1990-06-22 Phospholipase a2-inhibitor, mikroorganismen, die diesen inhibitor erzeugen und mehrere verfahren zu seiner herstellung.

Country Status (8)

Country Link
US (2) US5099034A (de)
EP (1) EP0405864B1 (de)
JP (1) JPH03108490A (de)
KR (1) KR910001037A (de)
AT (1) ATE121091T1 (de)
DE (1) DE69018529T2 (de)
DK (1) DK0405864T3 (de)
ES (1) ES2073529T3 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096923A (en) * 1990-03-21 1992-03-17 Merck & Co., Inc. Novel squalene synthetase inhibitors
US5132320A (en) * 1990-03-21 1992-07-21 Merck & Co., Inc. Squalene synthetase inhibitors
US5278064A (en) * 1991-08-01 1994-01-11 Eli Lilly And Company Amycolatopsis mediterranei strains useful to prepare A87689 compounds
US5350579A (en) * 1991-08-01 1994-09-27 Eli Lilly And Company A87689 compounds employed as a phospholipase A2 (PLA2) inhibitor to treat inflammatory diseases
US5254727A (en) * 1992-10-19 1993-10-19 Merck & Co., Inc. Acyclic tricarboxylic acid compounds
GB9226724D0 (en) * 1992-12-22 1993-02-17 Xenova Ltd Pharmaceutical compounds
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
SI1413331T1 (sl) * 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
EP1785144A3 (de) * 2001-01-26 2007-05-23 Shering Corporation Kombinationen von Gallensäurebinder(n) und Sterolabsorptionshemmer(n) und entsprechende Behandlung für vaskuläre Indikationen
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2434488A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DK1385548T3 (da) * 2001-01-26 2007-09-10 Schering Corp Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
JP4711600B2 (ja) * 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
WO2002096415A2 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
ATE411018T1 (de) * 2001-09-21 2008-10-15 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
WO2003101177A2 (en) * 2002-06-04 2003-12-11 Sequenom, Inc. Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
WO2004002295A2 (en) * 2002-06-27 2004-01-08 Sequenom, Inc. Diagnosing predisposition to fat deposition and associated condition
US20050014158A1 (en) * 2002-06-27 2005-01-20 Adam Gail Isabel Reid Therapeutic methods for reducing fat deposition and treating associated conditions
CA2504878A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1680189A2 (de) * 2003-11-05 2006-07-19 Schering Corporation Kombinationen von lipidmodulierenden mitteln mit substituierten azetidinonen zur behandlung von vaskularen erkrankungen
JP4606209B2 (ja) * 2005-03-10 2011-01-05 ダイセル化学工業株式会社 ラクトン化合物及びラクトン化合物の製造法
US7897800B2 (en) * 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
ES2328214B1 (es) 2008-05-06 2010-07-23 Consejo Superior De Investigaciones Cientificas Procedimiento de obtencion de las cinatrinas c3 y c1.
US20160184354A1 (en) 2009-01-23 2016-06-30 Jr Chem, Llc Rosacea treatments and kits for performing them
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
JP2013249293A (ja) * 2012-06-04 2013-12-12 Kao Corp リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943165A (en) * 1972-07-14 1976-03-09 Lever Brothers Company Esters of carboxymethyloxysuccinic acid and derivatives thereof
US4145437A (en) * 1975-08-21 1979-03-20 Imperial Chemical Industries Limited Hydroxy acids
GB8401149D0 (en) * 1984-01-17 1984-02-22 Fujisawa Pharmaceutical Co Furanone derivatives
IT1213330B (it) * 1986-08-28 1989-12-20 Rol Spa Tensioattivi derivati da idrossiacidi bi- o tri-carbossilici.
DE3830068A1 (de) * 1988-09-03 1990-04-05 Hoechst Ag Amidoamin-salze von alkenylbernsteinsaeurederivaten, verfahren zu deren herstellung und deren verwendung als korrosionsinhibitoren

Also Published As

Publication number Publication date
KR910001037A (ko) 1991-01-30
EP0405864A3 (en) 1992-01-08
ES2073529T3 (es) 1995-08-16
DE69018529T2 (de) 1996-03-21
DE69018529D1 (de) 1995-05-18
DK0405864T3 (da) 1995-07-03
EP0405864B1 (de) 1995-04-12
EP0405864A2 (de) 1991-01-02
US5120647A (en) 1992-06-09
JPH03108490A (ja) 1991-05-08
US5099034A (en) 1992-03-24

Similar Documents

Publication Publication Date Title
ATE121091T1 (de) Phospholipase a2-inhibitor, mikroorganismen, die diesen inhibitor erzeugen und mehrere verfahren zu seiner herstellung.
ATE229960T1 (de) Verfahren zur herstellung von 13-ether-derivaten von milbemycinen und zwischenprodukte
ATE206145T1 (de) Hyperverzweigte polyaspartatester und verfahren zu ihrer herstellung
DE69411243D1 (de) Verfahren zur herstellung eines lignan-derivats
ATE157973T1 (de) Carbazolon - derivate und verfahren zu ihrer herstellung
IL175350A0 (en) Method for the production of statins
DE3851022D1 (de) Verfahren zur Herstellung von verzweigten Fructo-Oligosacchariden.
DK92295A (da) Fremgangsmåde til fremstilling af 1,4-benzoquinoner
HUT65340A (en) Process for producing 1,5-benzotriazepine derivatives
CA2230826A1 (en) Galanthamine derivatives and process for their preparation
ATE34176T1 (de) 2'-chloropentostatin, eine diese verbindung enthaltende pharmazeutische zusammensetzung und ein mikroorganismus zur herstellung dieser verbindung.
DE68924991D1 (de) 2-Pyranon-Derivat und Verfahren zu dessen Herstellung.
ATE189887T1 (de) Vitamin-d-derivat und verfahren zu seiner herstellung
ATE137232T1 (de) Verfahren zur herstellung von 6-hydroxy-2,5,7,8- tetraalkyl-2-(4-aminophenoxymethyl)chromanen
DE3777464D1 (de) Fluorine enthaltende vitamin-d3-derivate und verfahren zu ihrer herstellung.
ATE123028T1 (de) Phospholipase-a2-inhibitor, verfahren zu seiner herstellung und diesen enthaltende pharmazeutische oder veterinäre zusammensetzungen.
ATE58142T1 (de) Valiolaminderivate und ihre herstellung.
ATE113608T1 (de) Antibiotikum.
ATE5583T1 (de) 4-methyl-3-formylpentensaeurealkylester, deren herstellungsverfahren, deren verwendung zur herstellung der 4-methyl-3-formyl-3-pentensaeure und die zwischenprodukte.
DE59804539D1 (de) 15-methyl-cyclopropanosteroide und verfharen zu ihrer herstellung
DE3772703D1 (de) Verfahren zur herstellung von penemen.
DE60008748D1 (de) Fluorinierte diole und verfahren zu ihrer herstellung
DE69108587D1 (de) Verfahren und Zwischenprodukte zur Herstellung von optisch aktiven Chromanderivaten.